Despite the development of novel therapeutics that are highly effective in lowering LDL-C, illustrated by increased use of PCSK9 inhibitors [31], the majority of our sample was unaware of these new medications, and only 38.1% would add ezetimibe to traditional statin treatment in severe cases of hypercholesterolemia. The gene discussed is PCSK9; the disease is Hypercholesterolemia.